Gaetano Vattemi

Dr. Gaetano Vattemi

Department of Neurosciences, Biomedicine and Movement Sciences, Section of Clinical Neurology, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in The American Journal of Pathology
Verified
Journal Article
Closed access
GVGaetano Vattemi
Gaetano Vattemi
WEW. King Engel
W. King Engel
JMJanis McFerrin
Janis McFerrin
VAValerie Askanas
Valerie Askanas

19 August 2010 in Rheumatology
Verified
Journal Article
Open access
PDF file
AGAnna Ghirardello
Anna Ghirardello
MRMariaelisa Rampudda
Mariaelisa Rampudda
LELouise Ekholm
Louise Ekholm
NBNicola Bassi
Nicola Bassi
ETElena Tarricone
Elena Tarricone
ADAndrea Doria
Andrea Doria
Objective. Serological testing for myositis-specific or associated autoantibodies [myositis-specific antibody (MSA) and myositis-associated antibody (MAA)] is useful for the diagnosis of idiopathic inflammatory myopathies (IIMs). However, available assays are neither standardized nor validated. The objective is to evaluate the accuracy of a commercial line blot assay for myositis diagnosis. Methods. IgG antibodies against Jo-1, PL-7, PL-12, PM/Scl, Ku, Mi-2 and Ro52 antigens were detected by a line blot and in-house RNA immunoprecipitation or immunoblot. We tested sera from 208 IIM patients, 50 healthy subjects and 180 control patients (11 non-autoimmune myopathy, 23 muscular dystrophy, 11 UCTD, 68 SLE, 36 SSc, 22 SS and 9 arthropathy). Results. MSAs or MAAs were detected in 98 (47%) out of the 208 IIM patients by line blot: anti-Jo-1 in 43 (21%), anti-PL-7 or anti-PL-12 in 8 (4%), anti-Mi-2 in 9 (4%), anti-PM/Scl in 9 (4%), anti-Ku in 10 (5%) and anti-Ro52 in 49 (24%). Overall specificity was: 100% for anti-Jo-1, anti-PL-7 or PL-12 and anti-PM/Scl; 96% for anti-Ku; 98% for anti-Mi-2; and 76% for anti-Ro52. In-house testing confirmed line blot results regarding anti-Jo-1, anti-PM/Scl and anti-Ku, while it was more accurate than line blot in detecting anti-Mi-2 (7 vs 4% sensitivity, 100 vs 98% specificity), and anti-aminoacyl-tRNA synthetase (anti-ARS) non-Jo-1 antibodies (11 vs 4% sensitivity, 97 vs 99% specificity). Conclusions. Line blot could be a suitable serological test in the diagnostic workup for myositis, and it represents a reliable alternative to more time-consuming procedures. Continuous effort is recommended in order to improve its accuracy.

10 September 2014 in Autoimmunity Highlights
Verified
Journal Article
Open access
PDF file
GVGaetano Vattemi
Gaetano Vattemi
MMMassimiliano Mirabella
Massimiliano Mirabella
VGValeria GUGLIELMI
Valeria GUGLIELMI
MLMatteo Lucchini
Matteo Lucchini
GTGiuliano Tomelleri
Giuliano Tomelleri
ADAndrea Doria
Andrea Doria
The gold standard to characterize idiopathic inflammatory myopathies is the morphological, immunohistochemical and immunopathological analysis of muscle biopsy. Mononuclear cell infiltrates and muscle fiber necrosis are commonly shared histopathological features. Inflammatory cells that surround, invade and destroy healthy muscle fibers expressing MHC class I antigen are the typical pathological finding of polymyositis. Perifascicular atrophy and microangiopathy strongly support a diagnosis of dermatomyositis. Randomly distributed necrotic muscle fibers without mononuclear cell infiltrates represent the histopathological hallmark of immune-mediated necrotizing myopathy; meanwhile, endomysial inflammation and muscle fiber degeneration are the two main pathological features in sporadic inclusion body myositis. A correct differential diagnosis requires immunopathological analysis of the muscle biopsy and has important clinical implications for therapeutic approach. In particular, unnecessary, potentially harmful, immune-suppressive therapy should be avoided alike in dystrophic myopathies with secondary inflammation.

13 June 2007 in Bioscience Reports
Verified
Journal Article
Closed access
PDF file
Massimiliano FilostoMassimiliano Filosto
Massimiliano Filosto
GTGiuliano Tomelleri
Giuliano Tomelleri
PTPaola Tonin
Paola Tonin
MSMauro Scarpelli
Mauro Scarpelli
GVGaetano Vattemi
Gaetano Vattemi
ASAlessandro Simonati
Alessandro Simonati
The term “mitochondrial diseases” (MD) refers to a group of disorders related to respiratory chain dysfunction. Clinical features are usually extremely heterogeneous because MD may involve several tissues with different degrees of severity. Muscle and brain are mostly affected, probably because of their high dependence on oxidative metabolism. Muscle can be the only affected tissue or involved as a part of a multi-system disease; ragged red fibers, accumulation of structurally altered mitochondria and cytochrome-c-oxidase (COX) negative fibers are the main pathological features. In mitochondrial encephalopathies, central nervous system (CNS) structures are affected according to different patterns of distribution and severity. Characteristic lesions are neuronal loss, vasculo-necrotic changes, gliosis, demyelination and spongy degeneration. In accordance with either grey matter or white matter involvement two main groups of diseases may be distinguished. Neuronal loss and vasculo-necrotic multifocal lesions are the common features of grey matter involvement; demyelination and spongy degeneration occur when white matter is affected, often associated with less severe lesions of the grey structures. Grey matter lesions are prevalent in MERRF, MELAS, Alpers and Leigh syndromes. White matter involvement is always seen in Kearns-Sayre syndrome and was recently described in mtDNA depletion syndrome linked to dGK mutations and in the rare conditions associated with complex I and II deficiency. In this review we describe the main histopathological features of muscle and CNS lesions in mitochondrial diseases.

12 August 2014 in Human Mutation
Verified
Journal Article
Closed access
PDF file
DRDaniela Rossi
Daniela Rossi
Bianca VezzaniBianca Vezzani
Bianca Vezzani
LGLucia Galli
Lucia Galli
CPCecilia Paolini
Cecilia Paolini
LTLuana Toniolo
Luana Toniolo
Vincenzo SorrentinoVincenzo Sorrentino
Vincenzo Sorrentino

11 September 2017 in Human Mutation
Verified
Journal Article
Closed access
PDF file
VBVirginia Barone
Virginia Barone
VRValeria Del Re
Valeria Del Re
AGAlessandra Gamberucci
Alessandra Gamberucci
VPValentina Polverino
Valentina Polverino
LGLucia Galli
Lucia Galli
Vincenzo SorrentinoVincenzo Sorrentino
Vincenzo Sorrentino